RT Journal Article
T1 Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
A1 Alonso, Rafael
A1 Cedena, María Teresa
A1 Gómez-Grande, Adolfo
A1 Ríos, Rafael
A1 Moraleda, José María
A1 Cabañas, Valentín
A1 Moreno, María José
A1 López-Jiménez, Javier
A1 Martín, Fernando
A1 Sanz, Alejandro
A1 Valeri, Antonio
A1 Jiménez, Ana
A1 Sánchez, Ricardo
A1 Lahuerta, Juan José
A1 Martínez-López, Joaquín
AB The value of minimal residual disease (MRD) status by bone marrow and imaging analysis as independent prognostic factors has been well established in multiple myeloma (MM). Nevertheless data about their potential complementarity for a more accurate assessment are limited. With this aim, we retrospectively analyzed the prediction of outcome with the combination of PET-CT and MRD, assessed by multiparameter flow cytometry (MFC) in 103 patients with newly diagnosed MM. We confirmed the benefit in terms of progression-free survival (PFS), linked to the achievement of negativity by MFC (hazard ratio [HR] 0.53; 95% confidence interval [CI]: 0.28-0.98), and PET-CT (HR 0.18; 95% CI: 0.09-0.36) individually. By combining both techniques, patients who became MRD-/PET-, with a median of PFS 92 months, had significant prolonged median PFS (P
YR 2019
FD 2019-06-09
LK http://hdl.handle.net/10668/13936
UL http://hdl.handle.net/10668/13936
LA en
DS RISalud
RD Jul 30, 2025